ArticleScientific reports2026
Association of plasma C1q/TNF-related protein 9 levels with disease severity and prognosis in patients with coronary atherosclerotic heart disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
C1q/tumor necrosis factor-related protein 9 (CTRP9) has been recognized as a factor associated with cardiovascular disease. Nevertheless, research regarding its relationship with the severity of coronary artery disease and the occurrence of adverse clinical events in coronary atherosclerotic heart disease (CAD) remains limited. A total of 302 patients were divided into mild lesion group and moderate-severe lesion group according to coronary artery complexity, determined by the SYNTAX scores. Major adverse cardiovascular events (MACEs) were assessed during a total follow-up of 21 months. The relationships of plasma CTRP9 levels with the severity of coronary artery stenosis and adverse prognosis were assessed in patients with CAD. Compared with the mild lesion group, the CTRP9 was significantly lower in the moderate-severe lesion group. In the receiver-operating characteristics (ROC) curve analysis, a cut-off CTRP9 value of 266.95 ng/mL was identified for predicting moderate-severe lesions. A total of 97 MACEs (32.12%) were documented after 21 months of follow-up. Multivariable Cox regression analysis revealed that decreased plasma CTRP9 levels independently predicted MACEs (HR: 0.996, 95% CI: 0.994–0.998, P < 0.001) after adjustment for potential confounding factors. Kaplan–Meier survival curves illustrated a significantly higher incidence of MACEs in patients with decreased CTRP9 levels compared with those with higher levels. Plasma CTRP9 levels were associated with the severity of coronary artery disease. Lower plasma CTRP9 levels were indicative of moderate-severe coronary lesions and an increased risk of MACEs in patients with CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.